PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020
17 mars 2020 08h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from ongoing research into investigational lysosomal-targeting cancer immunotherapy PV-10 (rose bengal...
Jounce Therapeutics Reports Second Quarter 2019 Financial Results
07 août 2019 06h30 HE | Jounce Therapeutics, Inc.
- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with...
Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
10 nov. 2018 12h20 HE | Jounce Therapeutics, Inc.
- Characterization of emerging ICOS hi CD4 T cells from responding patients provides rationale for JTX-2011 combination therapies - CAMBRIDGE, Mass., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Jounce...
Zyomyx Logo
Zyomyx Receives $7.5 Million From UNITAID to Launch Rapid, Service-Free Point-of-Care CD4 Test
26 mars 2014 07h30 HE | Zyomyx
FREMONT, Calif., March 26, 2014 (GLOBE NEWSWIRE) -- Zyomyx, Inc. has been awarded US$7.5 million from UNITAID to commercialize its quantitative MyT4™ point-of-care CD4 test, designed to guide...
Zyomyx Logo
Zyomyx Receives CE Mark for Its New MyT4(TM) Point-of-Care CD4 Test
09 janv. 2014 07h30 HE | Zyomyx
FREMONT, Calif., Jan. 9, 2014 (GLOBE NEWSWIRE) -- Zyomyx, Inc., a provider of innovative point-of-care diagnostic tests, announced today that it received the CE Mark for its MyT4™ point-of-care...